Cortexyme Inc.

1.95+0.0500+2.63%Vol 269.62K1Y Perf -96.61%
Jul 29th, 2022 16:00 DELAYED
BID1.91 ASK1.99
Open1.91 Previous Close1.90
Pre-Market- After-Market-
 - -  - -%
Target Price
10.33 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.14 
Earnings Rating
Buy
Market Cap70.49M 
Earnings Date
8th Aug 2022
Alpha-0.00 Standard Deviation0.36
Beta1.40 

Today's Price Range

1.860.00

52W Range

1.78121.98

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-
1 Month
-10.14%
3 Months
-40.18%
6 Months
-58.77%
1 Year
-96.61%
3 Years
-92.77%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRTX1.950.05002.63
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.64-0.72-12.50
Q03 2021-0.73-0.730.00
Q02 2021-0.70-0.74-5.71
Q01 2021-0.63-0.78-23.81
Q03 2020-0.60-0.73-21.67
Q02 2020-0.63-0.604.76
Q01 2020-0.43-0.61-41.86
Q04 2019-0.39-0.46-17.95
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.743.90Positive
9/2022 QR-0.760.00-
12/2022 FY-2.86-7.52Negative
12/2023 FY-2.08-1.46Negative
Next Report Date-
Estimated EPS Next Report-0.74
Estimates Count2
EPS Growth Next 5 Years %39.90
Volume Overview
Volume269.62K
Shares Outstanding36.15K
Shares Float25.49M
Trades Count1.88K
Dollar Volume558.29K
Avg. Volume446.30K
Avg. Weekly Volume360.87K
Avg. Monthly Volume513.96K
Avg. Quarterly Volume464.07K

Cortexyme Inc. (NASDAQ: CRTX) stock closed at 2.07 per share at the end of the most recent trading day (a -3.27% change compared to the prior day closing price) with a volume of 547.12K shares and market capitalization of 70.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Cortexyme Inc. CEO is Casey C. Lynch.

The one-year performance of Cortexyme Inc. stock is -96.61%, while year-to-date (YTD) performance is -84.55%. CRTX stock has a five-year performance of %. Its 52-week range is between 1.7821 and 121.98, which gives CRTX stock a 52-week price range ratio of 0.14%

Cortexyme Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -60.90%, a ROC of -67.48% and a ROE of -67.34%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cortexyme Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.74 for the next earnings report. Cortexyme Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cortexyme Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cortexyme Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cortexyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cortexyme Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.72, ATR14 : 0.19, CCI20 : -130.55, Chaikin Money Flow : -0.11, MACD : -0.15, Money Flow Index : 27.05, ROC : -16.53, RSI : 27.13, STOCH (14,3) : 15.00, STOCH RSI : 0.00, UO : 50.58, Williams %R : -85.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cortexyme Inc. in the last 12-months were: Caryn G. McDowell (Sold 10 800 shares of value $30 923 ), Christopher P. Lowe (Option Excercise at a value of $812 041), Christopher P. Lowe (Sold 9 926 shares of value $977 711 ), Margaret McLoughlin (Option Excercise at a value of $17 000), Margaret McLoughlin (Sold 1 000 shares of value $88 930 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (50.00 %)
Moderate Sell
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
-
0.00
-
0.00

Cortexyme Inc.

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.

CEO: Casey C. Lynch

Telephone: +1 415 910-5717

Address: 269 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

TipRanks News for CRTX

Tue, 22 Mar 2022 10:26 GMT Cortexyme (CRTX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 19:15 GMT Cortexyme (CRTX) Gets a Hold Rating from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits